Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

rial in mid-2008 for the treatment of cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on The Nordic Exchange (OMXS:BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer, atherosclerosis and ophthalmic diseases. In January 2007 the Company announced a major strategic alliance with American-based Genentech, Inc. in the cardiovascular field. These projects are based on a competitive and in substance patented technology platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abelló, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharm
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ...  The orders are for odour control projects in North ... Asia . "Bidding activity in 2015 ... and CEO. "After a high volume year for bidding in 2014, ... New Year.  The recent orders reflect the organization,s renewed focus on ...
(Date:3/3/2015)... 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and Chief Executive Officer of Neurocrine Biosciences, will ... Miami.   The live presentation takes place ... The presentation will be webcast and may be accessed ... Listeners are encouraged to visit the website ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies ... CFO, is joining its Board of Director as Chair ... officer at Zillow Group, Chad oversees all finance, treasury ... built the company,s core finance, treasury and accounting functions, ... and nine acquisitions. In 2013, he was named Puget ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Crown Bioscience, ... company, has launched a new Life Science division specializing ... preclinical research. , The first products released include ... controls, and soon to be released in vivo grade ... continue to expand their life science portfolio with additional ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2
... Nov. 13 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... of Savient Pharmaceuticals,will present a corporate update at the ... presentation is scheduled to begin on Tuesday, November 18, ... at the St. Regis Hotel in New,York City November ...
... Md., Nov. 13 PharmAthene, Inc.,(NYSE Alternext US: ... and chemical threats, today reported,financial and operational results ... 30, 2008., For the third quarter of ... $3.4 million in the same period of 2007. ...
... Biomaterial that Stops Bleeding Wins Professor Venture Fair at,U-Md. ... A University of,Maryland professor and doctoral student team who ... attention of a group of venture,capitalists and the title ... Nov. 12., Sponsored by the university,s Office of ...
Cached Biology Technology:Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 3Pharmathene Reports Third Quarter 2008 Financial and Operational Results 4Pharmathene Reports Third Quarter 2008 Financial and Operational Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 6Pharmathene Reports Third Quarter 2008 Financial and Operational Results 7Nano-Velcro Sticks With Venture Capitalists 2Nano-Velcro Sticks With Venture Capitalists 3
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has ... Market Overview" report to their offering. , ... that an individual is who she/he is claiming to be, ... a person,s unique physical characteristics, such as fingerprint, hand or ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... -- The Damon Runyon Cancer Research Foundation, a ... researchers and innovative cancer research, named 18 new ... Committee review. The recipients of this prestigious, ... and translational cancer research in the laboratories of ...
... discovered a dramatic increase of an easy-to-detect enzyme in the ... Hopkins scientists say the discovery could lead to a simple, ... before symptoms or complications occur and in time to reverse ... Diabetes , show the enzyme O-GlcNAcase is up to ...
... Researchers from Mount Sinai School of Medicine have identified a ... process by which information from a gene is used to ... which may help scientists gain insight into how muscle and ... of Nature . Using a combined approach of ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 5Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 6Hopkins team discovers sweet way to detect prediabetes 2Mount Sinai researchers discover new way diseases develop 2
... biologic production demands on cell and tissue ... cell populations. Therefore, both cell concentration and ... accurately and precisely. The new Vi-CELLTM Cell ... effective means to perform the trypan blue ...
... modification that plays an important role ... inflammation, cell-to-cell adhesion, and cell signaling. ... based Glycoprotein Isolation Kits, Concanavalin A ... that allow isolation of glycoproteins from ...
... SureLINK Bioconjugation Kit provides a powerful yet ... and nuceleic acids. The kit provides the ... reagents for quantifying conjugation efficiencies. It enables ... biotin and other tags with a variety ...
... The LS series of laser scanners is ... Expression Suite solution. ,Gene expression analysis, ... requirements essential to the advancement of ... rise to novel microarray formats and sizes. ...
Biology Products: